Supplemental Table 1. Sequence of treatments in trial and commercial cohorts

|  |  |  |
| --- | --- | --- |
| **n=182 pts** | **Trial** | **Commercial** |
| **First studied therapy** | **Immune (%)** | **Targeted (%)** | **Immune (%)** | **Targeted (%)** |
| **1st line** | 26 (49%) | 10 (48%) | 65 (72%) | 15 (83%) |
| **2nd line** | 22 (42%) | 10 (48%) | 13 (14%) | 2 (11%) |
| **3rd or later line** | 5 (9%) | 1 (4%) | 12 (13%) | 1 (6%) |

Supplemental Table 2. Correlation between time on therapy and toxicity

